NASDAQ: BIOABioage Labs Inc Stock
$24.34-0.55 (-2.21%)
Updated Jul 10, 2026
BIOA Price
$24.34
Fair Value Price
$7.25
Market Cap
$1.08B
52 Week Low
$4.11
52 Week High
$25.96
P/E
-10.14x
P/B
2.85x
P/S
72.02x
PEG
N/A
Dividend Yield
N/A
Revenue
$10.32M
Earnings
-$89.93M
Gross Margin
100%
Operating Margin
-867.09%
Profit Margin
-871.8%
Debt to Equity
0.05
Operating Cash Flow
-$88M
Beta
1.11
Next Earnings
Aug 5, 2026
Ex-Dividend
N/A
Next Dividend
N/A
BIOA Overview
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BIOA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
BIOA
Ranked#45 of 53
Ranked#45 of 53
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $177.11 | A | |
| $4.47 | A | |
| $17.01 | A |
Be the first to know about important BIOA news, forecast changes, insider trades & much more!
BIOA News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BIOA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BIOA ($24.34) is overvalued by 235.84% relative to our estimate of its Fair Value price of $7.25 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
BIOA ($24.34) is not significantly undervalued (235.84%) relative to our estimate of its Fair Value price of $7.25 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
BIOA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more BIOA due diligence checks available for Premium users.
Valuation
BIOA fair value
Fair Value of BIOA stock based on Discounted Cash Flow (DCF)
Price
$24.34
Fair Value
$7.25
Overvalued by
235.84%
BIOA ($24.34) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
BIOA ($24.34) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
BIOA is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
BIOA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-10.14x
Industry
-5.88x
Market
12.99x
BIOA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.85x
Industry
1.56x
BIOA is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BIOA's financial health
Profit margin
Revenue
$2.8M
Net Income
-$22.3M
Profit Margin
-802.8%
BIOA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
BIOA's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$397.7M
Liabilities
$18.5M
Debt to equity
0.05
BIOA's short-term assets ($391.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BIOA's short-term assets ($391.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BIOA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$24.0M
Investing
-$46.8M
Financing
$123.7M
BIOA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
BIOA vs Pharmaceutical Stocks
Bioage Labs Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.